Table 1.
Baseline characteristics
| Age (median ±SD) | 62.0 ± 7.7 |
| Sex | |
| M | 23 (60.5%) |
| F | 15 (39.5%) |
| Race | |
| White | 34 (89.5%) |
| Black | 4 (10.5%) |
| Zubrod performance status | |
| 0 | 9 (23.7%) |
| 1 | 25 (65.8%) |
| 2 | 4 (10.5%) |
| T stage | |
| T3 | 8 (21.1%) |
| T4 | 30 (78.9%) |
| N stage | |
| N0 | 14 (36.8%) |
| N1 | 24 (63.2%) |
| AJCC stage | |
| II | 7 (18.4%) |
| III | 31 (81.6%) |
| GTV (cm3) | |
| Median ±S.D. | 47.9± 44.0 |
| Range | 17.1–169.6 |
| CA19-9 (U/mL) | |
| Median | 156 |
| Mean | 839 |
| SD | 1335 |
| Range | 11–5028 |
| Interquartile range (25%/75%) | 46–996 |
| ≤90 | 15 (39%) |
| >90 | 23 (61%) |
Abbreviations: AJCC = American Joint Committee on Cancer; CA19-9 = carbohydrate antigen 19-9; GTV = gross tumor volume; SD = standard deviation.